cyrilzakka/clinical-trials huggingface dataset:
Community Burden of MG Infection

Objective: To assess the burden and the transmission dynamics of Mycoplasma genitalium (MG) infection in men who have sex with men in Hong Kong.

Design and setting: involving a) a cross-sectional study (completion of an online self-administered survey, followed by self-sampling for testing in the laboratory, and performance of HIV self-test); b) a mathematical modelling study to simulate the transmission dynamics of MG infection and resistant MG infection and compare the impacts of test-and-treat strategies.

Participants: Around 920 men who have sex with men would be recruited

Cross-sectional study: A total of 920 men who have sex with men aged 18 or above and normally living in Hong Kong would be recruited. Eligible participants would be asked to complete a self-administered online survey, submit self-collected urine specimen and rectal swabs for Chlamydia trachomatis, Neisseria gonorrhoeae, and Mycoplasma genitalium testing in the laboratory, and submit HIV self-test results.

Mathematical modelling study: A compartmental model would be constructed to simulate the transmission dynamics of MG infection and resistant MG infection, and analyse the impact of different test-and-treat strategies.

Eligibility Criteria:
Inclusion Criteria:

* men who have sex with men aged 18 or above, normally living in Hong Kong, and could communicate in written and spoken English or Chinese

Exclusion Criteria:

* cannot provide consent
Methodist Health System COVID-19 Patient Registry

This is a prospective cohort observational registry study that will include data on all patients who are treated at MHS facilities for COVID-19.

This is a prospective cohort observational registry study that will include data on all patients who are treated at MHS facilities for COVID-19. Data including, but not limited to demographics, comorbidities, medications, treatment, and clinical outcomes will be collected from February 2020 to December 2025. Subjects will undergo no additional tests or procedures as part of this registry study. All patient data will be obtained from the patient's electronic health records (EHR) of the hospital or clinic in a retrospective manner. The process for gathering the data will not influence treatment decisions. There will be no direct patient contact associated with inclusion in this registry study.

Eligibility Criteria:
Inclusion Criteria:

* Patient tested positive for COVID-19 (SARS-CoV-2)
* Patient sought care for COVID-19 at a MHS facility
* Aged 18 years or older

Exclusion Criteria:

* Patient that do not have COVID-19
* Non-confirmed COVID-19 patients
* Aged 17 years or younger
Reducing Hemarthrosis in ACL Reconstruction With BTB Autograft by the Administration of Intravenous TXA

The purpose of the proposed study is to evaluate the effects of administering intravenous tranexamic acid (TXA) to patients undergoing anterior cruciate ligament (ACL) reconstruction with bone-patellar tendon-bone autograft to minimize hemarthrosis within the knee joint and post operative pain.

The purpose of the proposed study is to evaluate the effects of administering intravenous tranexamic acid (TXA) to patients undergoing anterior cruciate ligament (ACL) reconstruction with bone-patellar tendon-bone autograft to minimize hemarthrosis within the knee joint and post operative pain. Patients received the standard arthroscopic ACL reconstruction with a BTB autograft and were randomized to either receiving or not receiving two individual doses of TXA intra-operatively or receive. The goal of the study is to determine and evaluate the effect of intra-operative TXA on post-operative hemarthrosis, pain reduction, and opioid consumption.

Eligibility Criteria:
Inclusion Criteria:

-PATIENTS UNDERGOING AN ACL RECONSTRUCTION WITH BTB AUTOGRAFT

Exclusion Criteria:

* Legally incompetent or mentally impaired (e.g., minors, Alzheimer's subjects, dementia, etc.)
* Younger than 18 years of age
* Any patient considered a vulnerable subject
* Have bleeding or clotting disorder
* Preoperative anticoagulation therapy
* Abnormal coagulation profile
* Renal disorder or insufficiency
* Sickle cell disease
Scapulo-Thoracic Mobilization Compared to IASTM in Patients With Mechanical Neck Pain

SCAPULO-THORACIC MOBILIZATION COMPARED TO IASTM IN PATIENTS WITH MECHANICAL NECK PAIN

Mechanical neck pain is common musculoskeletal condition that causes work disabilities and is not self-limiting. One of the main causes for mechanical neck pain is forward head posture, which is common and but not ideal posture adopted by many workers and students who presents with head being anterior to the shoulder. Imbalances in the normal muscle function reported in such patients with inhibited deep neck flexors, serratus anterior and rhomboids and tightened pectoralis, upper trapezius and levator scapula.

Neck and scapula have some common muscle attachments and abnormal loads on cervical or thoracic spine change the biomechanics of muscles present in these regions, which eventually cause trigger points Management of scapulo-thoracic joint focuses on correcting posture, restoring flexibility of the scapula including the pectoralis minor, levator scapulae, rhomboids, mobilization and soft tissue techniques.

IASTM is ergonomically designed stainless steel tool, and has recently gained much popularity for elevating pain, reducing trigger points and improving ROMs because it has deeply penetrating power as compared to mobilization through hand. This technique works by both along the mobilizing muscle fibers or parallel to the muscle fibers.

Eligibility Criteria:
Inclusion Criteria:

* Age group 18 to 40 years
* Both gender groups
* Non radiating neck pain

Exclusion Criteria:

* History of cervical and thoracic spine surgery
* Vertibro-basilar insufficiency
* Sign of serious pathology like malignancy
* Signs of systemic inflammatory disorder
* Patient with diagnosed hypertension
* (scapular area pathology)
Validity of Viome's Oral/throat Cancer Test

A total of at least 1,000 participants with suspicion of cancer including at least 107 subjects who will be diagnosed with OSCC or OPSCC will be enrolled from either primary or secondary care centers in the U.S. Clinicians will use Viome collection kits to collect saliva samples from eligible patients.

This is a prospective, multi-center study. Subjects with OSCC or OPSCC will be enrolled from four primary and secondary care centers in the U.S. Study samples will be collected by the clinicians at the study sites using Viome saliva sample collection kits. Patients will continue with their current health plan and confirm diagnosis following the standard of care of surgical biopsy with histology if needed. If a biopsy is performed, the result of the biopsy will be compared with the result of the Viome kit. If no biopsy is performed, the Viome test result will be compared with the physician's assessment based on clinical judgment. Patients with a positive result from histology will not receive the results of the Viome kit, and it will not play any part in the clinical management of the patients.

Eligibility Criteria:
Inclusion Criteria:

* Signed and dated informed consent prior to any study-specific procedures are performed
* Willing and able to follow the study instructions, as described in the recruitment letter
* Adults (18 years old or older)
* Suspicion of OSCC or OPSCC on clinical presentation by a clinician

Exclusion Criteria:

* Pregnancy
* Use of fertility enhancing medications
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery

The study will compare how well PF-06473871 works versus placebo in reducing skin scarring after scar revision surgery of existing breast scars. The study will also evaluate the safety of PF-06473871 in healthy adult subjects.


Eligibility Criteria:
Inclusion Criteria:

* Subjects must have hypertrophic (raised) breast scars from previous surgery
* Subjects must be healthy

Exclusion Criteria:

* Currently pregnant or pregnant during the 6 months, prior to inclusion in the study or breast-feeding.
* Presence of history of breast cancer
A Study of the Effect of INCB013739 on Cortisone Reducing Enzyme Activity in Obese People Predisposed to Diabetes

The purpose of this study is to determine whether the investigational drug INCB013739 has an effect on systemic and adipose tissue 11-HSD1 activity in obese, insulin resistant subjects.

"Proprietary Information: Exploratory (Non-Confirmatory) Trial".

Eligibility Criteria:
Inclusion Criteria:

* Male and female subjects between 18 years and 65 years of age.
* BMI between 30 and 42 kg/m2, inclusive.
* FPG \<126 mg/dL

Exclusion Criteria:

* Meet criteria for diagnosis of diabetes mellitus at the screening evaluation, female subjects with a history of gestational diabetes are permitted.
* Are receiving oral antidiabetic agents within the 3 months prior to screening.
Predicting Language Recovery in Acute Stroke Patients in the Neurovascular Intensive Care Unit: An Exploratory Study With the Core Assessment of Language Processing.

Introduction:

Stroke affects one person every 4 minutes in France (i.e. more than 140,000 new cases per year) resulting in cognitive and motor disorders. Aphasia is one of the most devastating cognitive disorders that persist in the late phase. However, early treatment of aphasia can improve the effects of rehabilitation.

Identifying, as early as possible, the patients most at risk of presenting persistent language disorders in the late phase would make it possible to improve their management and increase the effects of cognitive rehabilitation on their language abilities.

The aim of this project is to evaluate whether the Core Assessment of Language Processing (CALAP) assessed in the acute phase of stroke can predict language abilities in the late phase.

Hypothesis/Objective:

The primary objective is to determine whether the language abilities of patients in the acute phase of stroke can be used to predict language abilities in the late phase. Secondary objectives are to determine whether prediction can be improved with (1) brain MRI data and (2) neuropsychological assessment data. The final secondary objective is to determine whether the language abilities of an acute stroke patient can be used to predict his or her cognitive abilities in the late phase after stroke.

Method:

Patients will be included during their hospitalization after a brain vascular injury (acute phase, up to 21 days of hospitalization). After discharge, they will return for a post-stroke assessment between 3 and 18 months after the acute phase.

During these two visits, a clinical and neurological examination, a neuropsychological assessment and an MRI will be performed.

A prediction model (development and validation) will be used for all objectives using a linear regression model with cross validation. The entire sample consists of stroke patients.

The study is single-center and will have a total duration of 6 years with an estimated 570 patients included.

Conclusion:

Predicting the language abilities of a post-stroke patient will improve clinical management and direct patients requiring language rehabilitation to appropriate care.


Eligibility Criteria:
Inclusion Criteria:

* Age: between 18 and 85 years old
* Inpatient in the initial phase of stroke (between 0 and 21 days after stroke)
* Hemispheric stroke, ischemic or haemorrhagic
* Ability to participate in tests
* Francophone
* 4≤ NIHSS score ≤21 or if NIHSS score \< 4, LAST score \[0-13\]
* Non-opposition to participation in tests

Exclusion Criteria:

* Severe alertness impairment incompatible with test participation, NIHSS score 1a. different from 0
* Severe overall intellectual deterioration incompatible with test participation
* Patients who may have a visual or hearing impairment incompatible with participation in CALAP
* History of stroke
* Posterior fossa stroke
Study of the Paclitaxel-Coated Balloon Catheter in Bifurcated Coronary Lesions

This study in bifurcated coronary lesions compares the new technology of the paclitaxel-eluting balloon with the usual technique until now of "provisional stenting" with the paclitaxel-eluting stent in the main branch.

The bifurcated coronary lesions are still a challenge for interventional cardiologists, since there is no suitable technique or strategy to manage such lesions.

This multicenter randomized prospective trial in bifurcated coronary lesions will compare the new technology of the paclitaxel-eluting balloon with the until now "gold standard" technique of the "provisional stenting" with the paclitaxel DES in the main branch.

Eligibility Criteria:
Inclusion Criteria:

PATIENTS

* Patients with stable angina (1-3) or unstable angina (1-3 A-C) or documented silent ischemia
* Patients with mental and logistic conditions for the follow-up
* Patients should accept an angiographic follow-up at 9 months, a clinical follow-up at 3 years and sign the consent

LESIONS

* De-novo lesions in the bifurcations of DA/Diag either CX/OM or CD/DP with diameters in the main vessel of 2,5 to 3,8/ 2 to 3,5 and lengths \< 22 mm
* The left main lesions in bifurcation are also accepted but with another independent randomization list (specify at randomization)
* The diameter of the stenoses should be \>50% in any branch with documented ischemia or more than 70% in absence of an ischemia test
* Single vessel or multivessel disease
* In case of a PTCA of more than one lesion, the non included lesion should be treated previously to the included lesion

Exclusion Criteria:

PATIENTS

* Patients with STEMI \< 72 hours
* Patients with congestive heart failure or NYHA IV, shock or severe valvular heart disease
* Patients with short life expectancy, or with problems for platelet antiaggregation
* Patients in treatment with hyperthyroidism, in treatment with immunosuppression or anticoagulants, or with alcohol or drug addiction
* Patients included in other trials
* Patients with a stroke 6 months before
* Patients with a surgery one week before
* Severe renal failure calculated as GF \< 30 ml/min "Cockcroft Gault"
* Women of childbearing age, with probability to become pregnant during the first year of follow-up

LESIONS

* Evidence of important thrombus within the vessel to treat
* Patients with another stent previously implanted at ≤ 15 mm from the current lesion of the study
* Lesions affecting bypass
* Chronic occlusions to treat
* Restenosis in-stent or of a segment in 4 mm close to the target lesion
* Severe calcification not totally dilatable with the balloon
The Effects of Dexmedetomidine Dose on Motor Evoked Potentials

This a parallel group, two-arm, randomized superiority trial that will compare the effect of two different doses of dexmedetomidine on motor evoked potentials during spine surgery

This a parallel group, two-arm, randomized superiority trial that will compare the effect of two different doses of dexmedetomidine on suitability of motor evoked potentials for intraoperative monitoring during spine surgery

Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing multi-level posterior spine fusions requiring motor evoked potential monitoring

Exclusion Criteria:

* Allergy to dexmedetomidine, propofol
* Conditions knows to make recording of motor evoked potentials difficult, including poorly controlled diabetes, severe peripheral neuropathy, severe myelopathy, or previous surgery during which motor evoked potentials were difficult to obtain
* Hepatic disease
Verbal Synchrony, Satisfaction and Decision-making in Face-to-face Consultations

Eligible participants will be: benign thyroid nodules patients, to be involved in a consultation with their endocrinologist and/or surgeon and/or radiologist, in order to discuss treatment options related to benign thyroid nodules.

Eligible participants will be: benign thyroid nodules patients, to be involved in a consultation with their endocrinologist and/or surgeon and/or radiologist, in order to discuss treatment options related to benign thyroid nodules. Endocrinologist and/or surgeon and/or radiologist involved in the consultation will be recruited as well.

Before the scheduled consultation with endocrinologist, surgeon or radiologist, benign thyroid nodules patients will be screened for eligibility by a researcher and a physician from the Interventional Radiology Unit.

If patients meet all the inclusion criteria, they will be contacted by the researcher and proposed to participate. The day of the consultations, researcher will meet participants face to face, they will answer any questions should arise and will ask them to sign the informed consent form.

Benign thyroid nodules patients have a specific clinical pathway, in which they may have consultations with endocrinologists, and/or with surgeon, and/or with radiologists. Patients will be recruited before their first consultation and then, if they are scheduled to have other consultations with other professionals, will be recruited as well for the following consultations.

Eligibility Criteria:
Inclusion Criteria:

Specifically, to be eligible for the inclusion in this study, each patient has to fulfill all these criteria:

* diagnosis of benign thyroid nodule;
* scheduled consultation with endocrinologist and/or surgeon and/or radiologist to discuss treatment options related to benign thyroid nodule;
* ≥18 years old at the time of recruitment;
* proper understanding of Italian language;
* fluent Italian speaker;
* able to comply to requested procedures to obtain audio-video recording.

Each professional has to fulfill these criteria:

* proper understanding of Italian language;
* fluent Italian speaker;
* able to comply to requested procedures to obtain audio-video recording.

Exclusion Criteria:

• Patients with diagnosed mental or neurological disorder that could impair the participation will be excluded from the study.
Extended Release Naltrexone for Treating Amphetamine Dependence in Iceland

Until positive results were found with oral naltrexone, no medication has been effective against amphetamine dependence. The primary aim of this pilot study is to replicate the findings of the Swedish team that showed oral Naltrexone prevented relapse to amphetamine addiction and to extend their results by randomizing treatment-seeking amphetamine addicted patients to a 6 month course of VIVITROL (naltrexone for extended-release injectable suspension) or VIVITROL placebo. Patients in each group will receive drug counseling. VIVITROL is administered monthly and may be a better test of efficacy than tablets that must be taken daily.


Eligibility Criteria:
Inclusion Criteria:

1. Age 18 or above;
2. Diagnosis of amphetamine dependence as defined by DSM-IV-TR with 10 or more days of amphetamine use in the past month, and patient and clinician identify amphetamine dependence as the main problem;
3. Abstinent from substances (alcohol, amphetamines, cannabinoid, cocaine, hallucinogens, opioids, benzodiazepines \[unless used to treat alcohol withdrawal\] for at least 7 days prior to receiving study drug or placebo;
4. Provision of telephone numbers/contacts of three or more people that are likely to know where can be located if unable to be contacted directly;
5. Successfully complete 7-10 day assessment and study baseline measures at Vogur

Exclusion Criteria:

1. Any liver test \>5 times the top limit of normal; Physiologically dependent on opioids or other substances (nicotine excepted) at time of admission to Vogur;
2. Suspected or known concomitant use of opioid analgesics, positive opioid urine drug test or positive naloxone challenge:
3. Schizophrenia, Bipolar I or other non-substance related psychotic disorder; Severely depressed, suicidal or homicidal: Dementia: Inability to understand the informed consent;
4. Planning to move from the Reykjavík area or enter jail within the next 12 months;
5. Likely to receive opioid analgesics in next 6 months associated with possible or scheduled surgery or procedure;
6. Known hypersensitivity to naltrexone, polyactide-co-glycolide (PLG); carboxymethylcellulose, or any other component of the diluent;
7. Female subjects who are pregnant or lactating, or of child bearing potential who are not using acceptable methods of birth control;
8. A body habitus that precludes use of the customized needle for intramuscular injection, based on clinical judgment;
9. Use of an investigational agent in the past 30 days
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-315 in Healthy Japanese Males

To assess the safety and tolerability of ascending single oral doses of SAM-315, an investigational drug, in healthy Japanese male subjects.To obtain preliminary pharmacokinetic (PK) and pharmacodynamic (PD) profiles of SAM-315 in healthy Japanese male subjects.


Eligibility Criteria:
Inclusion criteria:

* Men aged 20 to 45 years (inclusive) at the time of getting informed consent.
* Body mass index (BMI) in the range of 18.5 to 25.0 kg/m2 and body weight≥50 kg (BMI = \[weight (kg)\]/\[height (m)\]2).
* Healthy as determined by the investigator on the basis of medical history, physical examination, clinical laboratory test results, vital signs, and digital 12-lead electrocardiogram (ECG). Alanine aminotransferase (ALT), aspartate aminotransferase (AST) and creatinine levels must be within the upper limit of normal for eligibility.

Exclusion criteria

* Any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease.
* Any clinically important deviation from normal limits in physical examination, vital signs, digital 12-lead ECGs, or clinical laboratory test results.
* Consumption of any caffeine-containing products (eg, coffee, tea, chocolate, or cola) or alcoholic beverages is prohibited from 48 hours and consumption of grapefruit or a grapefruit-containing products is prohibited from 72 hours before study day 1.
Rapid Extremity Pain Relief by Battlefield Acupuncture After Orthopedic Surgery

The purpose of this study is to determine if the addition of Battlefield Auricular Acupuncture (BFA) to standard therapy causes reduction in pain, medication use, time to ambulation without assistance, hours missed from work and increases quality of life after lower extremity surgery at two Air Force Medical Centers.

We will recruit 429subjects into this research study, for an expected 309 completing the study. We estimate 120 subjects will either withdraw consent or become ineligible for the study. Subjects will be ≥18 years or older and scheduled for lower extremity surgery. To randomize subjects, we will employ a random number generator, which will minimize difference between study groups. Additionally, we will collect data about patients' length of hospital stay, which will allow for statistical control of the variable, complexity of surgical procedure. The Research Assistants/Coordinators will be responsible for obtaining Informed Consent and HIPAA Authorization from subjects, collecting data, and de-identifying data prior to review and analysis by the Investigators. The Investigators will be responsible for ongoing protocol monitoring, insertion of needles, verifying inclusion/exclusion criteria, and analyzing data.

Eligibility Criteria:
THIS STUDY IS BEING CONDUCTED AT A MILITARY INSTALLATION. YOU MUST HAVE MILITARY INSURANCE IN ORDER TO PARTICIPATE IN THIS STUDY.

Inclusion Criteria:

Male and female subjects (DoD beneficiaries), 18 years or older who are scheduled for lower extremity surgery below the hip.

Exclusion Criteria:

Pregnant or breastfeeding Absence of their ear Active cellulitis of their ear Ear anatomy precluding identification of acupuncture landmarks Non-English speaking Use of Hearing Aids that preclude the insertion of ASP needles Inability to comply with study protocol